IDEXX Laboratories struggles with a 33.1% decline from its 52-week peak, trailing the broader market as investors weigh concerns over veterinary demand against the company's improved Q2 earnings performance.
IDEXX Laboratories' stock has underperformed the Dow, down 33.1% from its 52-week high, with technicals below key moving averages amid concerns over slower veterinary clinic traffic.
The Dow Jones Industrial Average has returned 3% over three months and 9% in 2026, outperforming IDXX.
Zoetis, IDEXX's biggest rival, has declined even more sharply, down 51.1% over the past 52 weeks.
A related headline quotes Nvidia CEO Jensen Huang's bullish AI outlook, likening AI to new electricity.
A related headline reports Rocket Lab stock jumping on new solar cell debut.
A related headline mentions Microsoft switching to two business segments, with unclear stock impact.
IDEXX Laboratories shares have tumbled 33.1% from their 52-week highs, significantly underperforming the Dow Jones Industrial Average. While the company faces headwinds from reduced veterinary clinic traffic, recent Q2 results show a 9.7% revenue increase, prompting management to raise its 2026 growth outlook.
The stock has faced pressure due to investor concerns regarding slower veterinary clinic traffic, which limits near-term growth prospects for the diagnostic services provider.
IDEXX has performed poorly, but its decline is less severe than that of Zoetis, which has dropped 51.1% over the past 52 weeks.